BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

  1. Homepage
  2. Medicinal products
  3. Pharmacovigilance
  4. Risk information

Dear Doctor Letter (Rote-Hand-Brief) on Revlimid® (lenalidomide): New important information on reactivation of virus infections

2016.11.08

Active substance: lenalidomide

The company Celgene GmbH is circulating information that cases of virus reactivation after treatment with lenalidomide have been reported.

Download DHPC/Information letter , Download_VeroeffentlichtAm_EN PDF, 335KB, File is accessible